/BIOC
Biocept, Inc.
BIOC • NASDAQBIOC • NASDAQ • Healthcare
$0.43+0.00%+0.00
$0.43+0.00%(+0.00)Healthcare
GoAI Score
Sign in to unlock
Valuation
50Fair Value
Sentiment
70Bullish
Risk
96Low Risk
Momentum
50Neutral
Institutional-Grade Intelligence
🏆PRO
Actionable Intelligence
AI-driven stance, execution logic & risk thresholds
Catalyst Roadmap
Event timeline with expected impact & market context
Deep Insights
Fact-checked analysis & score logic breakdown
Financial Statements
Margin Trends
Gross
-10.0%▼48.3pp
Revenue after COGS
Operating
-123.7%▼119.8pp
After operating expenses
Net
-124.1%▼119.5pp
Bottom-line profitability
Gross Margin
Operating Margin
Net Margin
Valuation Snapshot
P/E Ratio
-0.1
Price vs earnings
EV/EBITDA
-0.1
Enterprise value
FCF Yield
-470.6%
Cash generation
Earnings Yield
-1071.3%
Inverse of P/E
Capital Efficiency
-188
GoAI Quality ScorePoor
ROEReturn on Equity
-362.2%Weak
ROAReturn on Assets
-103.9%Weak
ROICReturn on Invested Capital
-117.6%Weak
Financial Health
Current RatioHealthy
2.97
Short-term solvency (>1.5)
Net Debt / EBITDAManageable
0.03x
Debt repayment capacity (<3x)
Income QualityWeak
0.41
Cash backs earnings (>1)
Revenue & Profitability
Revenue
Net Income
Net Loss
Income Statement
| Metric | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|
| Revenue | $25.86M | $61.25M | $27.46M | $5.53M | $3.25M |
| Gross Profit | -$2.58M | $23.48M | $6.12M | -$5.45M | -$6.80M |
| Gross Margin | -10.0% | 38.3% | 22.3% | -98.6% | -209.3% |
| Operating Income | -$31.98M | -$2.41M | -$15.47M | -$23.06M | -$24.26M |
| Net Income | -$32.09M | -$2.82M | -$17.04M | -$24.61M | -$24.57M |
| Net Margin | -124.1% | -4.6% | -62.1% | -445.2% | -756.0% |
| EPS | -$56.78 | -$5.73 | -$43.16 | -$357.54 | -$2634.46 |
Rating Distribution
Strong Buy
0
0%
Buy
1
33%
Hold
2
67%
Sell
0
0%
Strong Sell
0
0%
Recent Analyst Ratings
FirmActionRatingDate
Maxim Group▼ Downgrade
Buy→Hold
2023-04-14Feltl & Co.▲ Upgrade
Hold→Buy
2020-11-25Benchmark▼ Downgrade
Buy→Hold
2020-11-25Benchmark● Maintain
Buy
2020-11-25Feltl & Co.▲ Upgrade
Hold→Buy
2016-11-10Benchmark▼ Downgrade
Buy→Hold
2013-01-31Benchmark● Maintain
Buy
2012-10-18Earnings History & Surprises
BEAT RATE
18%
Last 11 quarters
AVG SURPRISE
-3417.5%
EPS vs Estimate
BEATS / MISSES
2/9
Last 11 quarters
LATEST EPS
$-9.91
Q4 '23
QUARTERLY EPS TREND
Estimated
Beat
Miss
QUARTERLY DETAIL
Q4 '23
No data
Q3 '23
No data
Q2 '23
No data
Q1 '23
-14702.3%
$-32.57 vs $-0.22
Q4 '22
-106.5%
$-9.91 vs $-4.80
Q4 '22
-5718.8%
$-9.31 vs $-0.16
Q2 '22
+33.4%
$-4.80 vs $-7.21
Q2 '22
No data
Q4 '21
-66.7%
$0.90 vs $2.70
Q3 '21
-2525.0%
$-4.20 vs $-0.16
Q2 '21
No data
Q1 '21
No data
No investor questions available.
Latest News
No news available